{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:20:28Z","timestamp":1791645628511,"version":"4.3.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,15]]},"DOI":"10.2146\/ajhp110256","type":"journal-article","created":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T21:54:41Z","timestamp":1343858081000},"page":"1405-1409","source":"Crossref","is-referenced-by-count":8,"title":["Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions"],"prefix":"10.1093","volume":"69","author":[{"given":"Kerry L.","family":"LaPlante","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Rhode Island, Kingston, and Adjunct Clinical Associate Professor of Medicine, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Woodmansee","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Laboratory, Providence Veterans Affairs Medical Center."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard A.","family":"Mermel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rhode Island Hospital, Providence, and Professor of Medicine, Department of Medicine, Warren Alpert Medical School of Brown University, Providence"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041607100782800_b1-0691405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis."},{"key":"2019041607100782800_b2-0691405","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1093\/cid\/cir257","article-title":"Guidelines for the prevention of intra-vascular catheter-related infections","volume":"52","author":"O\u2019Grady","year":"2011","journal-title":"Clin Infect Dis."},{"key":"2019041607100782800_b3-0691405","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2146\/ajhp070080","article-title":"Telavancin: a novel lipoglycopeptide antimicrobial agent","volume":"64","author":"Attwood","year":"2007","journal-title":"Am J Health-Syst Pharm."},{"key":"2019041607100782800_b4-0691405","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/AAC.00742-09","article-title":"Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies","volume":"53","author":"Kosowska-Shick","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607100782800_b5-0691405","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607100782800_b6-0691405","unstructured":"Vibativ (telavancin) for injection, for intravenous use. www.astellas.us\/docs\/us\/VIBATIV_PI_Final.pdf (accessed 2010 Feb 9)."},{"key":"2019041607100782800_b7-0691405","first-page":"231","article-title":"Successful treatment of haemodialysis catheter-related sepsis without catheter removal","volume":"8","author":"Capdevila","year":"1993","journal-title":"Nephrol Dial Transplant."},{"key":"2019041607100782800_b8-0691405","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00002018-200730050-00003","article-title":"Drug-related problems in hospitals: a review of the recent literature","volume":"30","author":"Kr\u00e4henbuhl-Melcher","year":"2007","journal-title":"Drug Saf."},{"key":"2019041607100782800_b9-0691405","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/ndt\/gfm141","article-title":"In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model","volume":"22","author":"LaPlante","year":"2007","journal-title":"Nephrol Dial Transplant."},{"key":"2019041607100782800_b10-0691405","first-page":"2361","article-title":"Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs","volume":"45","author":"Dasta","year":"1988","journal-title":"Am J Hosp Pharm."},{"key":"2019041607100782800_b11-0691405","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1592\/phco.30.1.35","article-title":"Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin","volume":"30","author":"Goldberg","year":"2010","journal-title":"Pharmacotherapy."},{"key":"2019041607100782800_b12-0691405","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/01.mat.0000183656.75618.09","article-title":"Prolonged stability of stored vancomycin, gentamicin, and heparin for use in the antibiotic-lock technique","volume":"51","author":"Bastani","year":"2005","journal-title":"ASAIO J."},{"key":"2019041607100782800_b13-0691405","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1542-4758.2009.00368.x","article-title":"Antibiotic lock: in vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37 degrees C","volume":"13","author":"Battistella","year":"2009","journal-title":"Hemodial Int."},{"key":"2019041607100782800_b14-0691405","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jac\/dki311","article-title":"Stability of heparin and physical compatibility of heparin\/antibiotic solutions in concentrations appropriate for antibiotic lock therapy","volume":"56","author":"Robinson","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"2019041607100782800_b15-0691405","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1046\/j.1523-1755.2002.00201.x","article-title":"Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution","volume":"61","author":"Krishnasami","year":"2002","journal-title":"Kidney Int."},{"key":"2019041607100782800_b16-0691405","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ndt\/gfh041","article-title":"Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen","volume":"19","author":"Poole","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"2019041607100782800_b17-0691405","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/ndt\/17.6.1149","article-title":"Treatment of haemodialysis catheter-related infections","volume":"17","author":"Vardhan","year":"2002","journal-title":"Nephrol Dial Transplant."},{"key":"2019041607100782800_b18-0691405","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1093\/ndt\/17.12.2189","article-title":"Superior antimicrobial activity of trisodium citrate over heparin for catheter locking","volume":"17","author":"Weijmer","year":"2002","journal-title":"Nephrol Dial Transplant."},{"key":"2019041607100782800_b19-0691405","unstructured":"Food and Drug Administration. FDA issues warning on tricitrasol. www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm173095.htm (accessed 2012 Mar 12)."},{"key":"2019041607100782800_b20-0691405","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jac\/dkm211","article-title":"Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus","volume":"60","author":"Saravolatz","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"2019041607100782800_b21-0691405","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/AAC.01642-08","article-title":"In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains","volume":"53","author":"LaPlante","year":"2009","journal-title":"Antimicrob Agents Chemother."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/16\/1405\/28455338\/ajhp1405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:20:45Z","timestamp":1555413645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/16\/1405\/5111993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,8,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110256","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,8,15]]},"published":{"date-parts":[[2012,8,15]]}}}